Logo

AstraZeneca's AZD7442 Meet its Primary Endpoints in P-III TACKLE Trial for the Treatment of COVID-19

Share this

AstraZeneca's AZD7442 Meet its Primary Endpoints in P-III TACKLE Trial for the Treatment of COVID-19

Shots:

  • The P-III TACKLE trial evaluates the safety & efficacy of AZD7442 (600mg- IM) as monothx. vs PBO in a ratio (1:1) in 903 outpatients aged ≥18yrs. who were non-hospitalized with COVID-19 & symptomatic for ≤7 days
  • The trial met its 1EPs i.e.- 50% reduction in risk of severe COVID-19 or death from any cause- was well tolerated. In prespecified analysis- 67% reduction in risk of severe COVID-19 or death from any cause
  • Additionally- 90% of patients were at high risk of progression to sev COVID-19 including co-morbidities. The company will discuss data with the authorities. On Oct 5- 2021- the company had submitted a request to the US FDA for EUA of AZD7442 to treat prophylaxis of COVID-19

Ref: AstraZeneca | Image: Al Jazeera

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions